Intravitreous (IVT) injection is the fastest growing procedure in ophthalmology. The number of IVT injections performed in the United States, estimated from Medicare procedure codes, increased from fewer than 3000 injections per year in 1999 to more than 1 million injections in 2008, and the number of injections will continue to increase given the aging population and the expanding indications.1
Because of the potential for severe vision loss, endophthalmitis remains the most feared complication after IVT injection, with a reported incidence ranging from 0.02% to 0.2%.2 However, because many retinal conditions require long-term serial injections, the cumulative risk per treated patient is more significant. Furthermore, several recent outbreaks of endophthalmitis have occurred in cities across the United States owing to contaminated bevacizumab, which has raised further safety concerns regarding this procedure. With the rapid increase in injections, this subject merits further review and summative assessments of best practice.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.